NFE2L2 and neoplasm: Furthermore, combining NFE2L2 inhibition with immunotherapies (e.g., CD19-targeted CAR T-cell therapeutics) could amplify tumor immunogenicity by increasing ROS accumulation and ferroptotic cell death, thereby boosting antitumor immune responses[138].